Further Discussion on Plasmids to Establish Release Specifications Using a Risk-Based Approach to Manage Supply

whitePaper | September 29, 2022

The market is experiencing a surge in the availability of cell and gene therapies (CGTs); it’s estimated that by 2025 as many as 20 will be introduced into the US each year.1,2

whitePaper | May 10, 2022

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines

whitePaper | May 29, 2023

tronger than expected US inflation and a bump in consumer spending have fuelled worldwide expectations that interest rates will go higher, as predictions about future monetary policy rapidly shift.

whitePaper | May 27, 2023

The Human Genome Project was a monumental effort over more than a decade to determine the human DNA sequence and analyze genetic variation among individuals. The hope was that, armed with this understanding, phenotypic differences would be explainable by genetic variation, and health benefits could follow.

whitePaper | November 10, 2022

The call for achieving representative diversity in clinical trials and development programs is not new and indeed dates back more than five decades in the United States but has been amplified over the course of the COVID-19

whitePaper | March 1, 2022

The Special Issue “Connecting materials science with fungal biology” celebrates recent breakthroughs in the fabrication of fungal-based materials, all of which have been made possible by the interdisciplinary and transdisciplinary collaboration of fungal biologists and biotechnologists with artists, designers, materials scientists, and architects